Abstract American Trypanosomiasis or Chagas disease is a prevalent, neglected and
serious debilitating illness caused by the kinetoplastid protozoan parasite Trypanosoma …

A multi-step cascade strategy using integrated ligand-and target-based virtual screening
methods was developed to select a small number of compounds from the ZINC database to …

Trypanosoma cruzi, a protozoan parasite, is the causative agent of Chagas disease, a major
cause of cardiovascular disease in many Latin American countries. There is an urgent need …

A century after discovering that the Trypanosoma cruzi parasite is the etiological agent of
Chagas disease, treatment is still plagued by limited efficacy, toxicity, and the emergence of …

The cysteine protease cruzipain is considered to be a validated target for therapeutic
intervention in the treatment of Chagas disease. Hence, peptidomimetic cruzipain inhibitors …

Chagas' disease is one of the most impactful and prevalent neglected tropical diseases in
the Americas, specially affecting the poor and underdeveloped areas in Latin America …

Over 110 years after the first formal description of Chagas disease, the trypanocidal drugs
thus far available have limited efficacy and several side effects. This encourages the search …

The development of cruzain inhibitors has been driven by the urgent need to develop novel
and more effective drugs for the treatment of Chagas' disease. Herein, we report the lead …

Trypanosoma cruzi, the causative agent of Chagas' disease, affects tens of millions of South
Americans. One of the most studied T. cruzi-biomolecules as a target for drug development …

The protozoan parasite Trypanosoma cruzi, the etiological agent of Chagas' disease, affects
millions of individuals and continues to be an important global health concern. The poor …